Mesoblast limited (ASX:MSB) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.79 and traded as high as $1.98. Mesoblast shares last traded at $1.90, with a volume of 4,527,725 shares trading hands.
The company has a current ratio of 0.86, a quick ratio of 0.75 and a debt-to-equity ratio of 18.77. The firm has a market capitalization of $940.74 million and a price-to-earnings ratio of -12.50. The firm has a 50 day moving average price of A$1.79 and a two-hundred day moving average price of A$1.63.
About Mesoblast (ASX:MSB)
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Read More: Net Margin
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.